Thu, Jan 29, 2015, 6:03 AM EST - U.S. Markets open in 3 hrs 27 mins

Recent

% | $
Quotes you view appear here for quick access.

SciClone Pharmaceuticals, Inc. Message Board

snogreen 198 posts  |  Last Activity: 9 hours ago Member since: Aug 30, 2000
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • Reply to

    Where do I even start

    by thebasiles777 10 hours ago

    Whaaaa? You say:

    "As far as our share price goes our short will still work his game until revenues are on the near horizons."

    Aren't you skipping a few steps? revenues? There is not yet a single statistically worthy trial of TB 4 anywhere, toi get approval or revenues!!!! . So before you hype revenues and a soaring stock.....focus on the Lee's trial.....I highly doubt that the brand new Koreans biotech company will do much of anything until they see how Lee's China trial went..and NO WAY will Koreans ever spend the many millions needed for USA trials --- until they see what Lee's comes up with. Focus on the important one....Lee's dry eye China.

  • snogreen snogreen 13 hours ago Flag

    Well, if that is the sum total of your knowledge and investment research...that the JBSAY chart looks "terrible"....then good luck to you, you don't have a clue of what JBS is or does.The Brazialn Real tanked with the strong dollar and collapsing oil. Over 70% of JBS revenues in US Dollars. when translated back into Reals, a fortune is made. But just as good, with the Real tanking.......it means that to buy goods in Brazil just got a lot cheaper..that means EXPORTS will grow faster and JBS is a huge exporter of products..........they are large suppliers to KFC and McDonalds....and both those companies will be buying BIG from JBS with the super strong dollar. Beef & chicken prices are much lower in Brazil as well. Mark my words....in March JBS will report a block buster quarter. And around the same time, they will make a big M&A deal, most likely a US firm (that should be PPC's acquisition). Charts are junk. In 30 years I have never once met a rich chartist.

  • snogreen snogreen 13 hours ago Flag

    THat is just silly. PBR is controlled by the gov't. JBSAY is controlled by the family that started it. Furthermore, over 70% of JBS revenues are in US Dollars. JBS is huge, you have no idea how big. And PPC is their piggy bank when they need a billion or so,

  • snogreen snogreen 14 hours ago Flag

    Yup. I figured that out a while ago. I sold PPC and bought JBSAY....in the low to mid $7's. JBSAY is a far better deal and they own 75% of PPC. But the currency swings are there.

    No one on this board has figured it out. PPC is run for the pleasure of JBSAY, not PPC shareholders. This $1.5 BILLION dividend was ridiculous. PPC had a pristine balance sheet, now they will be debted up big time.for what? Siimple answer. JBSAY is using PPC as their "piggy bank savings account". So when JBSAY needed $1.2 billion cash, they made PPC pay a huge dividend. It was NOT MEANT for you retail holders! It was meant for JBS! Next up? what you will see is that JBS takes the $1.2 billion from PPC and JBS buys a very big company....a chunk of it paid for BY YOU SHAREHOLDERS of PPC!....thank you $1.2 billion. the company that JBS buys shoudl have, by all rights, been bought by PPC, so PPC can diversify from chicken.. Didn't happen. PPC is worse off for it. FIRST because they will soon be debted up about $2 billion. And SECOND.....JBS is taking the next company themselves, when PPC is the one in need of diversiying beyond tight chicken margins usually. IMO? in next 3 years you will make far more $$ in JBSAY, than PPC.

  • Reply to

    Great Deal for RGRX Shareholders

    by bocamp1 15 hours ago
    snogreen snogreen 14 hours ago Flag

    You never answered a single thing I said. you just go back to ancient SCLN? ONE stock? I been doing this a long time and I own and play many stocks. What I lost in SCLN was made back within a year. Not big deal....and it washed other profits i had that year as well.

    But back to RGRX. If the Korea and China soon dry eye trials are so wonderful and exciting, why did RGRX leaop at the chance to exit all USA rights for eyes for $1 million and a few other things? That eye NK phase 3 approved orphan trial is worth far more than that to some pharma. And as I said, if Lee's trial dry eye works...the USA rights are worth 10, 20, 30 times the $1 million RGRX just soldl them for. This is a so-so deal - at best. What it guarentees is that Finkelstein always wins. There's enough money to pay him $125,000 a year for a good handful of years. he wins. If trials flop, Finkle loses on stock, but he still pass "Go" and collects $125,000 regardless. No matter what happens, Finkel Tinkel wins.

  • Reply to

    Great Deal for RGRX Shareholders

    by bocamp1 15 hours ago
    snogreen snogreen 15 hours ago Flag

    It's a so so deal, for RGRX. Between the FDA granting RGRX Orphan status for eye NK, and then the FDA approvong direct to a Phase 3 trial..then why on earth did RGRX sell ALL the eye area..eye NK and dry eye too.....for $1 million for ALL US rights? Do you know what a big & real pharma pays to get a drug up to the Phase 3 stage? Tens or even hundreds of millions. So RGRX has a Phase 3 orphan trial OKAYED by FDA......worth barely $1 million??? And also, if you are so confident in the China trial, and Korea.why didn't Finkel wait to see if China trial wins. Because if China trial wins, USA rights for Phase 3 trial Orophan eye NK and druy eye are worth 10-20...maybe 30 TIMES the $1 million he just took. He'll probably only get $1 million for neuro now.

    Glad you're bidding! I hope you make a killing. i'm holding pat.

  • Reply to

    Korean wake-up call?

    by fl_geezer 16 hours ago
    snogreen snogreen 15 hours ago Flag

    Nah, It's pretty clear to me the game plan by Finkel..is to sell off what USA rights he can......he's sold skin and today sold eyes, for $1 million........so my guess is he tries to sell neuro next for $1 million. Neuro has backing of Henry Ford's research. I doubt there's much interest in heart, yet.

    So then RGRX collects and sits on a few million $$. RGRX no l;onger does any trial, nor any pre clinical work. They roll down to a 2 room office and let almost all who still around, go. Finkel and Goldie will still collect their $$..Finkies all set. He'll then get $125,000 a year for playing computer games and waiting for others to do trials. But if these are the best deals he can get.....then he had no choice. But I honestly thought Ora Inc woudl have found one of their big eye clients willing to pay more than $1 million for eyes.

    If the Lee's trial in China dry eye starts sometime soon......and that trial works? Then it wil look awfully stupid that Finkel sold all USA eye rights for $1 million. The fact that Finkel did not WAIT for the China trial results, is a clue of is confidence in it ?????. he took anything he could get, beforehand. ME? I woudl have gambled and waited for Lee's to finish.

  • Reply to

    news is only so-so

    by snogreen 17 hours ago
    snogreen snogreen 16 hours ago Flag

    You missed it again, bo. The dilution risk of 5.5 million shares to G Tree is NOTHING compared to what woudl happen if RGRX decided to sell 40 or 50 MILLION shares at 10 cents to fund a trial like neuro. The 5 million dilution from G Tree is nothing compared to that risk. Disagree all you want....but the fact that RGRX sold G Tree all skin rights for almost nothing and sold G tree all USA eye rights for $1 million and some royalty and small JV interest........that leads that all RGRX can get for neuro or heart is maybe $1 million. So after RGRX sells all USA eyes for $1 million, my guess is they will try to do the same for heart or neuro....$1 million and royalty. Then there are no more stock sale diluting and RGRX not belly up anytime soon. But then RGRX just becomes a shell of a company.....waiting on otherst o do trials. Guess that is better tyhan RGRX doing them.

  • Reply to

    news is only so-so

    by snogreen 17 hours ago
    snogreen snogreen 16 hours ago Flag

    Hey, you take it as negative, I see it as just the truth. G Tree already got USA rights for all TB 4 in skin area for almost nothing. G Tree just got ALL the TB 4 eye area for $1 million. So G Tree got all skin and eye. Only area left is neuro. henry Ford will probably find somone to take it, since now RGRX has done a USA deal for TB 4 rights for only $1 million. Once RGRX sells neuro , then that is it. All RGRX does is pay the office rent and Finkel plays computer games and waits. The only other possibility is cosmetic fragments. But it read to me like G Tree got all TB 4 skin rights?

    The only over the top good news I saw is that RGRX will have enough money now to just sit and wait. But the MM's were playing RGRX for either more massive dilution, or what they really wanted..RGRX bankrupt. No more big dilution, and RGRX will not go BK anytime soon.

  • I'm not that excited about the news G Tree is getting USA dry eye and eye NK TB 4 rights. They are unproven entity. It also points that RGRX sold all the eye TB 4 rights for $1 million, and royalties if any later. Now, why couldn't Ora Inc find a large US or European eye pharma client they have, to take TB 4 for eyes for a measly $1 million? I guess no interest. So maybe RGRX had no choice.

    The other good or bad is that RGRX just set the price precident. A major TB 4 indication for ALL USA rights, can be bought for $1 million. RGRX just did. SO??? That just set the porice for the TB 4 in neuro areas...price for thatt is now $1 million only. no pharma will pay RGRX $5 or $10 million for TB 4 neuro, if G Tree got eyes for $1 million. So what this tells me is that RGRX will now offer to sell TB 4 neuro for around $1 million. At that point, RGRX is DONE as an entity ongoing. Then all RGRX is a "sitter". RGRX won't do anymore thrial thus, others will. RGRX won't do any more pre clinical, all done. RGRX just sits and lets Lee's, G Tree and whoever buys neuro for $1 million......and if any work, RGRX just collects royalty or milestones. The REALLY GREAT news is that the MM's who are short a few million RGRX, play it for RGRX going bankrupt and to ZERO. RGRX is not going BK now. RGRX is selling all it's TB 4 rights. then RGRX pays office rent and a couple salaries and WAITS it out. Bankrupt won't happen for a couple/few years and only if every trial flops. MM'sp layed RGRX as BK much sooner. Won't happen now.

  • Reply to

    Deal reached

    by thebasiles777 19 hours ago
    snogreen snogreen 19 hours ago Flag

    It is a double edged sword, this stock purchase. If they don't do it, RGRX does not get $825,000 which puts RGRX in financial straits. but if Koreans do buy the stock, RGRX get's $825k....BUT RGRX ALSO get's a lot more DILUTION...because it is 5,500,000 more new shares. Dilution always hurts. That is why you see so many shares offered for sale, be it by a long or a short..dilution. Only thing to savve will be significant news...like a partner deal with REAL big pharma. Korea trial will mean little. Lee's will mean much more. But since most people believe that TB 4 flopped in USA dry eye, they thus believe it won't work in China dry eye. So even on the news that Lee's STARTS the China dry eye..few people outside this board will care. Which is why it is SO CRITICAL that RGRX disclose all the Lee's trial protocol! But somthing tells me RGRX will not disclose......and without that disclosure no one outside of us will play the China trial....and we soon get diluted again.

  • Opps! Do a searcgh for the journal 'Expert Opinion in Biological Therapy".......the early online edition posted Jan 22.......the first article is by Dr. Chopp..but there is a SEWCOND TB 4 abstract about reserachers doing a mouse study of TB 4 in 'Sepsis". Here is abstract......TWO abstracts TB 4 same Journal.

    "Objective: The actin polymerization regulator Thymosin β4 (Tβ4) has been shown to be involved in angiogenesis, wound healing, cell survival and anti-inflammatory responses. We have previously shown that Tβ4 is capable of recruiting pericytes, thus stabilizing the endothelial barrier function. Here, we analyzed whether treatment with Tβ4 is able to reduce the pericytes loss in lipopolysaccharides (LPS)-induced sepsis and to improve the hemodynamic function and survival in C57BL/6 mice.

    Methods: Fourteen days before LPS injection, the mice were injected with an adeno-associated virus carrying the Tβ4 (rAAV.Tβ4) or LacZ gene (rAAV.LacZ). A sepsis-severity score was assessed, and non-invasive hemodynamic and permeability measurements were performed. Heart and muscle samples were analyzed for PECAM-1+ capillaries and NG2+pericytes.

    Results: At 36 h, there was a decrease of sepsis severity score in rAAV.Tβ4-treated animals as compared to rAAV.LacZ-treated control. rAAV.Tβ4-treated animals displayed lower perivascular leakage and higher blood pressure compared to control. Of note, the rAAV.Tβ4 group showed a higher pericyte count in heart and peripheral muscle samples. Finally, Tβ4-treatment reduced mortality compared to control.

    Conclusion: The data indicate a preventive role of Tβ4 in septic hypercirculation and highlight Tβ4 as a potential therapeutic target in severe sepsis."

    Maybe some day someone will care......I think this is abstract 4,982 on TB 4 work.

  • New abstract out by Dr. Chopp of Henry Ford on TB 4 and neuro. More of a summary type piece. Read well. But I wish they (or someone else) woudl pick up teh ball with it. Henry ford's done about 6 years pre clinocal stuff....time to poop or get off the pot and do something. Get more info on it PubMed.

    "Thymosin β4 as a restorative/regenerative therapy for neurological injury and neurodegenerative diseases.
    Chopp M1, Zhang ZG.

    Abstract
    Thymosin β4 (Tβ4) promotes CNS and peripheral nervous system (PNS) plasticity and neurovascular remodeling leading to neurological recovery in a range of neurological diseases. Treatment of neural injury and neurodegenerative disease 24 h or more post-injury and disease onset with Tβ4 enhances angiogenesis, neurogenesis, neurite and axonal outgrowth, and oligodendrogenesis, and thereby, significantly improves functional and behavioral outcomes. We propose that oligodendrogenesis is a common link by which Tβ4 promotes recovery after neural injury and neurodegenerative disease. The ability to target many diverse restorative processes via multiple molecular pathways that drive oligodendrogenesis and neurovascular remodeling may be mediated by the ability of Tβ4 to alter cellular expression of microRNAs (miRNAs). However, further investigations on the essential role of miRNAs in regulating protein expression and the remarkable exosomal intercellular communication network via exosomes will likely provide insight into mechanisms of action and means to amplify the therapeutic effects of Tβ4."

  • Reply to

    Chicken margins

    by kpolhj Jan 21, 2015 9:05 AM
    snogreen snogreen Jan 24, 2015 10:46 AM Flag

    There's nothing bogus what I said. Why is it you KEEP quoting end of quarter results THAT ARE FROM THE 3RD QUARTER! they are meaningless! You won't have teh latest Q4 numbers till early February.

    Second, have you READ any of the news releases??? In second week of Dec 2014, PPC retired $500 million of 7 7/8% debt. So DON'T keep quoting Q3 stats! PPC had before that $856 million cash. They used $500 million of that in december to buy back $500 million debt. That leaves $356 million. But PPC is soon to close on buying Tyson's Mexican operations for $400 million. But PPC only has cash $356 million. That puts PPC in the hole for $34 million. THEN? with a negative $34 million, PPC pays a $1.5 billion special dividend. So that, with the negative $36 milion means PPC is in the hole $1.536 BILLION. Next? PPC only announced that it got a BANK loan for $600 million from RaboBank to help pay the dividend. Bank loans and bank lines of credit are usually short term in nature. They are a good way to finance until PPC can hit up the debt market and sell a ton of bonds. PPC has to pay the $1.5 bill dividend, they have to pay $400 million for Tyson Mexico....and they have to refinace the $500 million debt they retired. The good news is that when PPC hits up a big debt offering, rates will be very low and favorable. Still? i'm "neutrally positive" on PPC, but not excited about it now. It's clear to me that JBS is now using PPC for it's piggy bank, So JBS can use PPC's money (YOUR MINORITY SHAREHOLDERS MONEY) $1.2 billion so they can buy the next deal for themselves, NOT PPC!

  • Reply to

    best case scenario

    by thebasiles777 Jan 23, 2015 11:24 AM
    snogreen snogreen Jan 23, 2015 11:44 AM Flag

    Don't get your hopes up for "double news" next week. everything in China takes a lot longer than one wishes. Only way to speed things up was a little" graft"..but China has cracked down on that....so probably in reaction, thos ethat used to depend on it..but can't now...slow things down as a reaction. I hope it is soon......but be prepared to wait perhaps up to the full 10 months. hope not. And this Korea outfit? they are secondary. No big pharma looking at TB 4 trials will give what they do much creedence. Korea is just aas corupt. And this G-Treechanges it's company business every few years. One year iG Treeis a high tech business......this year it's biotech.. but Lee's is the real deal, and their trial results will be noticed. Hope they are good

  • Reply to

    Ora, similar new dry eye drug trial

    by snogreen Jan 22, 2015 1:05 PM
    snogreen snogreen Jan 22, 2015 1:34 PM Flag

    For all in my previous post, TRIAL DESIGN is the key to hoped for success......and good execution by a good & trusted CRO. Everyone can talk up Lee's or Korean joint as much as you wish...but no one will give RGRX the time of day until there is transparancy of what the heck the Korea and China trials are about. No one knows. No one is saying. How do we know that they aren't using as their primary endpoint the cornea INFERIOR region that TB4 already didn't make statical? See? If RGRX does not disclose the mere trial design, then no one will play it for the trial. The only way you are going to take out all these large short sale offers by the MM's, which hold RGRX close to broke, is to GET INVESTOR INTEREST! You don't get that by hiding trial designs, or screwing up every trial you have designed in the last decade.

  • Go to Ora Inc website for news. Ora is about to start a 150 pt Phase 2 for a new dry eye drug. It is similar to TB 4 in that is also a "naturally occuring molecule". but I can't find much else on it. You can search clinical trials site under the company name Harantis......a european firm. But the big thong, and saddest thing, is that I compared the trial design of their Ora phase 2 to our Ora design phs 2. The Herantis trial is far more broad and wide open. the TB 4 trial was narrow and overly specific in ONE subsection (or four) in cornea. RGRX would only test for statistical in the INFERIOR region cornea. Herantis uses the WHOLE cornea region. the upshot was that RGRX got STATISTICAL efficacy in TWO regions of teh whole cornea, but they did not in the single trial design INFERIOR region. So teh FDA and pharma says TB 4 flopped. Design for infereior region ONLY. but this Heratis trial has a wide, wide brushstoke to use the whole cornea and it's subsections. So if it works in a couple, it is a trial win. Once again (time and time again0 RGRX screwed up[ the trial design.just like they screwed up venous and pressure ulcer trial design. Here is exact wording. First one is Herantis. Second one was RGRX.

    Primary Outcome Measures:
    • Corneal Fluorescein Staining [ Time Frame: Day 29 ]
    • Symptom Score [ Time Frame: Day 22 to 28 ]

    Primary Outcome Measures:
    • Corneal Staining (Inferior Region) in the Worst Eye in the Controlled Adverse Environment (CAE) Model, Which is a Regulated Environmental Setting Aimed at Exacerbating the Signs and Symptoms of Dry Eye [ Time Frame: Day 29 (end of treatment) ] [

    Ocular Discomfort in the Worst Eye in the Controlled Adverse Environment(CAE) Model, Which is a Regulated Environmental Setting Aimed at Exacerbating the Signs and Symptoms of Dry Eye. [ Time Frame: Day 29 (end of treatment) ]

  • B7 is right. Yesterday 139,000 RGRX traded. Of that 110,000 was SHORTED. It never ends. ever. All NITE does is short and short. BAd. The SEC reports there is ZERO..yes "0" shares shorted in RGRX. Over 80% of all volume yesterday was short. So there is no way they could buy, sell, buy, sell and cover.....like MM's do in liquid high volumes stocks they make a market in. All NITe does is short and short and short more. And I've said that by now I figure NITE is doing a POSITION ttrade short RGRX at least 2,000,000 shares...probably closer to 3.000,00 0by now. Marketr Makers are not supposed to abuse SEC rules to take large and long term POSITION trades (long or short). The short sale rules exemptions the SEC gives them are only to be used in the daily course of making a market to buy and sell....not to "position" All NITE does is sell and scare. This also means that NITE is naked short RGRX, because MM's are exempt from borrowing or reporting the short.

    I wish the Lee's trial woudl start. They are the key right now.....I doubt many people or potential partnet firms will give much creedance to teh Korea one. But Lee's is the real deal.

  • Reply to

    Chicken margins

    by kpolhj Jan 21, 2015 9:05 AM
    snogreen snogreen Jan 21, 2015 8:57 PM Flag

    Do yourselves a BIG favor. if you like PPC? DON'T buy it! You can buy PPC by buying JBSAY. JBSAY owns 75% of PPC! And JBS just sucked out $1.2 BILLION from PPC, so JBS can buy the BEST M&A deals for themselves! Wake up! Why do you think the CFO of PPC sold many shares a while ago! Buying JBS in Brazil (JBSAY) is a far better bet.........you get ALL JBS assets worldwide, Brazil and 75% of PPC. the only bummer is the currency swings. You all better wake up. Something BIG changed in PPC and JBS. Ask yourself WHY JBS woudl allow PPC to bid on Hillshire to about $6 billion, but now JBS changes it's mind and they turn to PPC to SUCK $1.2 billion out of it! JBS has no intent on paying s stupid huge dividend, that is DOUBLE taxed to outside shareholders, YOU! JBS sucks money out of PPC so THEy can do the next big M&A deal on THEIR books! You wait and see. My guess is JBS buys out SEB. But SEB would have been better off with PPC, because it woudl diversify PPC hugely OUT of pure chicken low margins - just like TSN has dome so well. Mark my words. JBS is on a big deal --and they just robbed PPC bank account $1.2 billion to pay for it. NEVER, ever fporget that if you own PPC, you are subservient to whatever wishes, whims.......that 75% owner JBS desires. And do NOT think for a second that JBS is NOT out for themselves..... forget you minority 25% shareholders. After this massive, stupid dividend, I am neutral on PPC. I don't own it now. But I increased what I own in JBSAY big time ,when it is down. JBS has just neutered PPC..with far too much debt. Piggy JBS, but they win.

  • yesterday of 85,000 traded, 36,000 was shorted........so NITE ain't giving in. I'd love to see that 90,000 block today being all short too..which woudl also point to all that supposed 1 million shares offered higher....isn't long..but MM showing size to offer short to keep it down. Tonite be interesting.

    BTW the SEC is NOW REPORTING that there is 0....that's right, ZERO shares short in RGRX!

SCLN
7.40+0.03(+0.41%)Jan 28 4:00 PMEST

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.
Facebook, Inc.
NASDAQWed, Jan 28, 2015 4:00 PM EST
Nokia Corporation
NYSEWed, Jan 28, 2015 4:01 PM EST